Collectively, these data raise the possibility that modulating the SLC2A9-encoded transporter (GLUT-9) might be an alternative approach for urate-elevating therapy, compared to urate precursor administration as a potential PD treatment target. This evidence concerns the gene SLC2A9 and Parkinson disease.